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ime to Address the Cardiac
etabolic “Triple Whammy”
schemic Heart
ailure in Diabetic Patients*
ohn D. Horowitz, MBBS, PHD,
ennifer A. Kennedy, PHD
delaide, Australia
he prevalence of congestive heart failure (CHF), chronic
schemic heart disease, and diabetes mellitus is increasing in
ost societies, and it is not surprising that in most large
linical trials of CHF at least 75% of patients have under-
ying ischemic heart disease while approximately 20% to
5% of patients have diabetes (1,2). There is strong evidence
hat the presence of diabetes in patients with CHF is an
ndependent marker of adverse prognosis (3), and it has
lso been suggested that outcomes tend to be worse in
atients with ischemic, as distinct from non-ischemic,
ardiomyopathy (4).
See page 2225
Intriguingly, 2 studies (5,6) have taken this association
ne step further by evaluating the possibility of differential
rognostic impact of diabetes in ischemic versus non-
schemic CHF. In the SOLVD (Studies of Left Ventricular
ysfunction) trials, adjusted analyses suggested that diabe-
es was associated with a 37% increase in all-cause mortality
n patients with ischemic cardiomyopathy as well as with
ncreased risks of progression of symptoms, whereas there
as no similar association in non-ischemic subjects (5). A
imilar analysis of patients in the BEST (Beta-Blocker
valuation of Survival) trial reached remarkably similar
onclusions (6). Although it might be suggested that these
ndings might simply reflect an increased risk of (re)infarc-
ion in the diabetic/ischemic patient cohort, this did not
ppear to explain the overall excess mortality (6). An
lternative hypothesis, raised by the investigators who ini-
ially documented this association (5), is that myocardial
etabolism and energetics may be differentially perturbed,
epending on the presence/absence of ischemia in patients
ith heart failure.
There is considerable evidence that the failing heart is in
state of energy deficit. For example, in both animal models
nd humans, CHF is associated with reductions in cardiac
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiology Unit, The Queen Elizabeth Hospital, The University of
delaide, Adelaide, Australia.hosphocreatine (PCr), adenosine triphosphate (ATP), and
Cr:ATP ratios (7,8).
Moderate to severe CHF is also associated with changes
n myocardial substrate utilization (9), which may modulate
his energetic deficit, in part by impairment of efficiency of
yocardial oxygen utilization. The majority of human
tudies have demonstrated increased myocardial utilization
f fatty acids in class II to III CHF of both ischemic (10)
nd non-ischemic origin (11), although in very advanced
on-ischemic cardiomyopathy there is down-regulation of
atty acid metabolism, with increased uptake of glucose
12,13). Similarly, animal studies have demonstrated rela-
ively normal myocardial substrate metabolism in moderate
eart failure with fatty acid utilization predominating
14,15), whereas down-regulation of fatty acid oxidation
nd enhanced glucose utilization characterizes more severe
ecompensated heart failure (15). Enhanced glucose utili-
ation in late-stage heart failure appears to be a consequence
f the reduced fatty acid oxidation rather than due to a
irect enhancement of the glucose pathway, because some
nzymes of the carbohydrate metabolic pathway are down-
egulated, not up-regulated (16,17).
Myocardial responsiveness to insulin is potentially of
ivotal importance as a determinant of the extent of
yocardial glucose oxidation. Whole body and skeletal
uscle insulin resistance is characteristic of diabetes and has
lso been documented extensively in patients with CHF
oth of ischemic and non-ischemic origin (11,18–20) and
lso in the presence of ischemic heart disease without either
iabetes or CHF (18). However, a previous carefully con-
ucted study by Utriainen et al. (21) in diabetic and control
ubjects without CHF demonstrated no evidence of myo-
ardial, as distinct from skeletal, muscle, or whole body,
nsulin resistance. This study, which corrected for determi-
ants of myocardial work under normoglycemic hyperinsu-
inemic conditions, concluded that in the absence of myo-
ardial ischemia (or CHF), the myocardium is unlikely to
evelop an energetic deficit related to impaired glucose
ptake. Nevertheless, there is some evidence for a myocardial
nergy deficit in diabetic hearts. Scheuermann-Freestone et al.
22) demonstrated reduced PCr/ATP in hearts from patients
ith type 2 diabetes without evidence of cardiac dysfunction,
Cr/ATP correlating negatively with plasma non-esterified
atty acid concentrations, and, therefore, potentially reflecting
mpairment of glucose utilization.
In this issue of the Journal, Dutka et al. (23) have
nvestigated the impact of diabetes on myocardial insulin
ensitivity in a group of patients with CHF secondary to
ultivessel coronary artery disease who were undergoing
yocardial positron emission tomographic evaluation of
yocardial viability as a screening test for possible surgical
evascularization. During hyperinsulinemic glucose clamp,
yocardial glucose utilization, measured via uptake of
8F-fluorodeoxyglucose was significantly lower in diabetic
han in non-diabetic patients, indicating the presence of
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December 5, 2006:2232–4 Editorial Commentnsulin resistance at the myocardial level. Given that insulin
ensitivity in non-diabetic CHF patients was itself impaired
in comparison with historical control subjects), this finding
mplies that CHF per se and diabetes contribute incremen-
ally to myocardial insulin resistance in patients with con-
omitant myocardial ischemia.
These important findings beg 3 further questions. First, is
here any available information regarding the impact of
iabetes on myocardial insulin resistance in patients with
HF but no coronary disease? This important experiment,
hich would offer a possible explanation for previous
linical findings (5,6), unfortunately has not yet been per-
ormed by any group in the clinical setting.
Second, what is the signal transduction mechanism
hereby diabetes increases myocardial insulin resistance?
ne likely possibility is that expression of the myocardial
lut-4 glucose transporter, or translocation of Glut-4 to
yocardial cell membranes in response to insulin, may be
mpaired. In the absence of diabetes, reduced expression of
lut-4 has been observed in the rat infarction model of
eart failure (24), whereas reduced translocation of Glut-4
as been observed in a canine model of advanced heart
ailure (25). In the current study, left ventricular biopsy
amples in a subset of patients showed no variation in
lut-4 protein expression in the diabetic patients compared
ith those without diabetes, but this does not exclude a
efect in Glut-4 translocation. Alternatively, as suggested
y the authors, it is possible that the somewhat higher
oncentrations of free fatty acids in the subjects with
iabetes during the hyperinsulinemic euglycemic clamp-
nduced inhibition of glucose uptake.
The final issue raised by the current report by Dutka et al.
23) is whether specific therapeutic avenues should be
onsidered for patients with concomitant ischemic heart
isease, diabetes, and CHF. The crux issue here remains
ne of “chicken and egg”: can we be completely confident
hat the energetic deficit seen in patients with CHF, and
resumably particularly in the diabetic/ischemic subset,
ctually contributes directly to the impairment of contrac-
ility and to poor outcomes, or might it represent a conse-
uence of “myocardial hibernation”? Importantly, therapeu-
ic avenues are now opening up to test this hypothesis.
lthough the therapeutic potential of thiazolidinediones in
HF is limited by the risk of aggravation of symptoms (26),
number of “metabolic” agents are now showing promise
or the management of CHF. Perhexiline, an inhibitor of
he carnitine palmitoyltransferase system responsible for the
ptake of long-chain fatty acids across mitochondrial mem-
ranes (27), markedly improved functional status and he-
odynamics in patients with moderately severe CHF (28).
owever, perhexiline appeared to have similar beneficial
ffects in both ischemic and non-ischemic CHF. Further-
ore, preliminary studies with trimetazidine, which acts
argely as a partial inhibitor of mitochondrial fatty acid
xidation (29) in patients with class II to III CHF,
ndicated improvement in left ventricular systolic function30,31). Fragasso et al. (30) showed that these benefits were
lso seen in a small diabetic/CHF/ischemic cohort. The
urrent study by Dutka et al. (23) suggests that it may be
ime to perform adequately powered therapeutic trials to test
he Koch’s postulates for this group of high-risk patients.
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ardiology Unit, The Queen Elizabeth Hospital, The University
f Adelaide, 28 Woodville Road, Woodville SA 5011, Australia.
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